Glioma Cell Invasion: Regulation of Metalloproteinase Activity by TGF-β

Matrix metalloproteinases (MMPs) are a family of extracellular endopeptidases that selectively degrade components of the extracellular matrix. MMPs are implicated in tumor cell invasion because they mediate the breakdown of the basal membrane. In addition, they seem to be important for the creation and maintenance of a microenvironment that facilitates tumor cell survival. Among the essential characteristics of human malignant gliomas are infiltrative growth, angiogenesis and suppression of antitumor immune surveillance. Transforming growth factor-beta (TGF-β) is intimately involved in the regulation of these processes. We have previously demonstrated that TGF-β promotes the migration of LN-18 and LN-229 glioma cells via a process that may involve the upregulation of αVβ3 integrin expression. Furthermore, we have defined a novel pathway for hepatocyte growth factor (HGF)-induced glioma cell migration and invasion which requires the induction of TGF-β2 expression. Here, we demonstrate that TGF-β2 induces MMP-2 expression and suppresses tissue inhibitor of metalloproteinases (TIMP)-2 expression and that concentration-dependently promotes the invasion of U87MG and LN-229 glioma cells in a matrigel invasion assay. Similarly, ectopic expression of the anti-apoptotic BCL-xL protein leads to enhanced matrigel invasion by LN-18 and LN-229 glioma cells. We outline the possible interrelations of TGF-β, proteins of the BCL-2 family, integrins and metalloprotease activity. By virtue of its promotion of glioma invasion and its growth regulatory and immunomodulatory properties, TGF-β continues to be one of the most promising targets for the experimental therapy of human malignant glioma.

[1]  D. Mercola,et al.  The Transcription Factor EGR-1 Directly Transactivates the Fibronectin Gene and Enhances Attachment of Human Glioblastoma Cell Line U251* , 2000, The Journal of Biological Chemistry.

[2]  M. Martin,et al.  TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? , 2000, International journal of radiation oncology, biology, physics.

[3]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[4]  Y. Maehara,et al.  Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Tonn,et al.  Interactions of glioma cells and extracellular matrix , 2005, Journal of Neuro-Oncology.

[6]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[7]  J. Furuyama,et al.  Expressions of matrilysin and stromelysin in human glioma cells. , 1993, Biochemical and biophysical research communications.

[8]  D. Rifkin,et al.  Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.

[9]  M. Hasegawa,et al.  Transforming Growth Factor‐β1 Stimulates Contraction of Human Glioblastoma Cell‐Mediated Collagen Lattice through Enhanced α2 Integrin Expression , 2000 .

[10]  M. Nakanishi,et al.  Transforming growth factor-beta1 stimulates contraction of human glioblastoma cell-mediated collagen lattice through enhanced alpha2 integrin expression. , 2000, Journal of neuropathology and experimental neurology.

[11]  H. Moses,et al.  Transforming growth factor production by chemically transformed cells. , 1981, Cancer research.

[12]  J. Wrana,et al.  The Smad pathway. , 2000, Cytokine & growth factor reviews.

[13]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[14]  Y. Kaneda,et al.  Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney , 1996, Nature Medicine.

[15]  J. Dichgans,et al.  Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. , 2000, Biochemical and biophysical research communications.

[16]  R. Iozzo The Biology of the Small Leucine-rich Proteoglycans , 1999, The Journal of Biological Chemistry.

[17]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[18]  J. Dignam,et al.  Structural characterization of the latent complex between transforming growth factor beta 1 and beta 1-latency-associated peptide. , 1996, The Biochemical journal.

[19]  M. Weller,et al.  Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-β2 , 2001, The Journal of Neuroscience.

[20]  M. Platten,et al.  Malignant glioma biology: Role for TGF‐β in growth, motility, angiogenesis, and immune escape , 2001 .

[21]  J. Dichgans,et al.  N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) inhibits transforming growth factor‐β release and reduces migration and invasiveness of human malignant glioma cells , 2001, International journal of cancer.

[22]  Z. Gokaslan,et al.  In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor , 1997, Oncogene.

[23]  K. Miyazono,et al.  Enhanced expression of transforming growth factor‐β and its type‐I and type‐II receptors in human glioblastoma , 1995, International journal of cancer.

[24]  M. Abe,et al.  Cell-associated activation of latent transforming growth factor-beta by calpain. , 1998, Journal of cellular physiology.

[25]  M. Weller,et al.  Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. , 2001, Biochemical and biophysical research communications.

[26]  A. Baker,et al.  Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3 , 1999, British Journal of Cancer.

[27]  A. Angelucci,et al.  Osteoblast‐derived TGFβ‐1 modulates matrix degrading protease expression and activity in prostate cancer cells , 2000 .

[28]  R. Herbst,et al.  Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. , 1997, In vivo.

[29]  H. Ikeda,et al.  Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. , 1996, Biochemical and biophysical research communications.

[30]  M. Weller,et al.  Molecular determinants of glioma cell migration and invasion. , 2001, Journal of neurosurgery.

[31]  Y. Goto,et al.  The effect of tranilast on experimental proliferative vitreoretinopathy , 1999, Graefe's Archive for Clinical and Experimental Ophthalmology.

[32]  J. Massagué,et al.  Transcriptional control by the TGF‐β/Smad signaling system , 2000 .

[33]  G. Pilkington,et al.  The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells , 1999, British Journal of Cancer.

[34]  A Rimner,et al.  Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. , 2001, Cancer research.

[35]  L. Myeroff,et al.  Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. , 1998, Cancer research.

[36]  G. Pilkington,et al.  Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. , 1994, British Journal of Cancer.

[37]  J. Uhm,et al.  The role of integrins in the malignant phenotype of gliomas. , 1999, Frontiers in bioscience : a journal and virtual library.

[38]  J. Tonn,et al.  ECM‐mediated glioma cell invasion , 1998, Microscopy research and technique.

[39]  J. Dichgans,et al.  Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo , 1998, Gene Therapy.

[40]  Y. St-Pierre,et al.  In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. , 1998, Biochimica et biophysica acta.

[41]  T. Thompson,et al.  Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. , 1999, Molecular biology of the cell.

[42]  K. Miyazono,et al.  Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. , 1992, The Journal of biological chemistry.

[43]  廣井 信,et al.  ハムスター実験膵癌モデルにおけるN-[3,4-Dimethoxycinnamoyl]-Anthranilic Acid(Tranilast)の抗腫瘍効果 , 2002 .

[44]  J. Tonn,et al.  Effect of synthetic matrix‐metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas In vitro , 1999, International journal of cancer.

[45]  T. Tsuzuki,et al.  Neural cell adhesion molecule L1 in gliomas: correlation with TGF-beta and p53. , 1998, Journal of clinical pathology.

[46]  R. Leduc,et al.  Processing of Transforming Growth Factor 1 Precursor by Human Furin Convertase (*) , 1995, The Journal of Biological Chemistry.

[47]  J. Massagué,et al.  The transforming growth factor-beta family. , 1990, Annual review of cell biology.

[48]  A. Strongin,et al.  Matrix metalloproteinase-2 activation modulates glioma cell migration. , 1997, Journal of cell science.

[49]  N. Nagy,et al.  Human ex vivo carcinoma cells produce transforming growth factor β and thereby can inhibit lymphocyte functions in vitro , 1997, Cancer Immunology, Immunotherapy.

[50]  Jian-ming Li,et al.  Sp1, but not Sp3, functions to mediate promoter activation by TGF-beta through canonical Sp1 binding sites. , 1998, Nucleic acids research.

[51]  O. Monni,et al.  Identification and Characterization of a New Latent Transforming Growth Factor-β-binding Protein, LTBP-4* , 1998, The Journal of Biological Chemistry.

[52]  M. Olman,et al.  Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. , 1995, The American journal of pathology.

[53]  L. Liotta,et al.  Metastatic potential correlates with enzymatic degradation of basement membrane collagen , 1980, Nature.

[54]  T. Hada,et al.  Excessive production of transforming growth-factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth , 1992 .

[55]  J. Dichgans,et al.  Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses , 1998, International journal of cancer.

[56]  Erwin G. Van Meir,et al.  Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.

[57]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[58]  Adriano Fontana,et al.  The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain , 1995, Brain Research Reviews.

[59]  J. Dichgans,et al.  BCL‐2 promotes migration and invasiveness of human glioma cells , 1998, FEBS letters.

[60]  A. Angelucci,et al.  Osteoblast‐derived TGF‐β1 modulates matrix degrading protease expression and activity in prostate cancer cells , 2000, International journal of cancer.

[61]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[62]  K. Schlingensiepen,et al.  Effects of Transforming Growth Factor‐β1 on Collagen Synthesis, Integrin Expression, Adhesion an Invasion of Glioma Cells , 1995 .

[63]  M. Abe,et al.  Cell‐associated activation of latent transforming growth factor‐β by calpain , 1998 .

[64]  M. Czyz,et al.  Selective Sp1 and Sp3 binding is crucial for activity of the integrin alphaV promoter in cultured endothelial cells. , 1999, European journal of biochemistry.